Lonza Biologics Guangzhou, China in numbers

17
thousand m2 site plus significant adjacent expansion land secured
4,447
m2 laboratories and pilot plant
1,436
m2 cGMP facilities

Development and manufacturing services available

Lonza Biologics Guangzhou is a multiproduct facility for clinical and commercial supply. The site capabilities include single-use bioreactors at 200L, 1,000L and 2,000L and downstream processing equipment. The site employs GS Xceed® platform technology and leverages the experience of our global network.


  • Upstream capabilities

    • Mammalian cell culture processes (CHO, NS0, HEK etc.)
    • cGMP cell banking suite
    • Inoculum train bioreactors capacity from 25L to 500L
    • Production bioreactors of 200L, 500L, 1,000L and 2,000L single-use bioreactors
    • Harvest by depth filtration
    • Pre-packed and loose resin chromatographic columns
    • Viral inactivation
    • Single-use ultrafiltration / diafiltration
    • Bulk filling in to bags
    • Cell line development laboratories
    • Raw material, in-process and final product QC release testing
    • Microbiological testing
    • Drug substance and drug product stability study storage & testing

Quality systems and regulatory inspections

Our global quality system has consistently demonstrated compliance with major global regulators i.e. FDA, EMA, PMDA, ANVISA, TGA. It also meets China NMPA requirement. The same rigorous quality management systems, documentation practices, training and oversight will be applied to the Guangzhou facility to ensure one global quality standard.